On March 2nd, we had the pleasure of welcoming Polyceutix and DTU - Technical University of Denmark to officially launch the Eurostars project SyNaPoC, co-funded under the EUREKA Eurostars Programme.
🔬 This ambitious 24-month project aims to develop PLX-001, a next-generation immunotherapy based on nanodisc-forming polymers, designed to stimulate the immune system directly at the tumor site and improve the treatment of muscle-invasive bladder cancer and other solid tumors.
Within the consortium:
• Polyceutix brings its innovative therapeutic platform and scientific vision
• Antineo contributes its expertise in advanced preclinical oncology models, in-vivo CDX models, biological characterization, and translational strategy
• DTU provides its cutting-edge research expertise to support the project
Over the coming months, the consortium will focus on:
• Evaluating the therapeutic concept in biologically relevant models
• Validating preclinical safety and efficacy
• Generating robust data to support future first-in-human clinical trials
• Strengthening the translational pathway toward clinical applications
Beyond the scientific objectives, SyNaPoC highlights the value of cross-border collaboration in accelerating high-impact innovation across Europe.
We look forward to advancing this exciting journey toward more effective, targeted, and accessible therapeutic solutions for patients.
